
Science Resources RSS Feeds
|
 |
 |
 |
Fungal pill could provide asthma relief for 150,000 UK sufferers
December 29, 2008
Research could mean asthma relief for millions worldwide Up to 150,000 people suffering from severe asthma in the UK could benefit from taking antifungal medication already available from pharmacists, new research has found.
University of Manchester scientists found that pills used to treat everyday fungal infections greatly improved symptoms of asthma in those patients that had an allergic reaction to one or more fungi.
The study, carried out at four hospitals in northwest England and published in the American Journal of Respiratory and Critical Care Medicine, is the first to show that antifungal therapy can improve the symptoms of those who suffer from severe asthma.
The researchers compared the oral antifungal drug itraconazole with a placebo over eight months and found that nearly 60% of patients taking the drug showed significant improvement in their symptoms.
"Only patients with a positive skin or blood test for fungal allergy were included in the study," said Professor David Denning, who is based at the University Hospital of South Manchester.
"Severe asthma affects between five and 10% of adult asthmatics and probably 25 to 50% of these patients showed allergy to one or more fungi. Since about 60% of those treated benefited from the treatment, we believe that antifungal therapy may be helpful in as many as 150,000 adults with asthma in the UK."
The clinical study of 58 patients at the University Hospital of South Manchester, Salford Royal, Royal Preston and North Manchester General hospitals showed statistically significant improvements in a validated quality of life score. Patients' asthma and nasal symptoms deteriorated within four months of stopping therapy.
Dr Robert Niven, from The University of Manchester and the University Hospital of South Manchester, said: "This pioneering study indicates that fungal allergy is important in some patients with severe asthma, and that oral antifungal therapy is worth trying in some difficult-to-treat patients. Clearly itraconazole will not suit everyone, and is not always helpful, but, when it is, the effect is dramatic."
Dr Ronan O'Driscoll, at Salford Royal Hospital, added: "It's good news for patients with severe asthma to have an existing anti-fungal drug recognised as having benefits for asthma patients with fungal allergy. We found that many patients were only picked up by extensive skin and blood test screening for fungal allergy, so a change of clinical practice will be required to identify all the patients who might respond to itraconazole."
University of Manchester
|
 |
|
|
Pocket Guide to Systemic Antifungal Therapy
by MD & Geral Vincent T. Androle (Author)
|

|
FungaSoap Cleansing Wash
by Pedifix
Washes Away Fungus & Bacteria fro Skin's SurfaceSoothes Itching from Athlete's Foot & Skin IrritationsCleans & Deodorizes. Enriched with Tea Tree Oil
|

|
Pedinol Pharmacal Fungoid Tincture, Topical Antifungal, 1-Ounce Bottle
by Pedinol Pharmacal
Fungoid Tincture is a non-prescription branded product containing miconazole nitrate 2% in a novel, patented vehicle developed to enhance penetration. Fungoid Tincture is an effective, safe and cost-effective topical treatment for superficial fungal infections of the skin in and around the finger and toenail area. Fungoid Tincture is used in the treatment for certain infections of the skin. Podiatrists have recommended Fungoid Tincture since as early as 1925. Fungoid Tincture carries a seal of approval from the American Podiatric Medical Association.
|
|
|
Echinocandins offer antifungal therapy with low toxicity, few drug-drug interactions.(Infectious Diseases): An article from: Internal Medicine News
by Damian McNamara (Author)
This digital document is an article from Internal Medicine News, published by International Medical News Group on May 15, 2005. The length of the article is 615 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Echinocandins offer antifungal therapy with low toxicity, few drug-drug interactions.(Infectious Diseases) Author: Damian McNamara Publication: Internal Medicine News (Magazine/Journal) Date: May 15, 2005 Publisher: International Medical News Group Volume: 38 Issue: 10 Page: 63(1)
Distributed by Thomson...
|
|
|
Antifungal therapy interruption safe in AIDS patients with immune recovery. (Immune Recontitution with HAART).: An article from: Internal Medicine News
by International Medical News Group (Publisher)
This digital document is an article from Internal Medicine News, published by International Medical News Group on December 15, 2002. The length of the article is 1304 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Antifungal therapy interruption safe in AIDS patients with immune recovery. (Immune Recontitution with HAART). Publication: Internal Medicine News (Magazine/Journal) Date: December 15, 2002 Publisher: International Medical News Group Volume: 35 Issue: 24 Page: 37(1)
Distributed by Thomson...
|

|
Antifungal Drug Therapy
by Paul Jacobs (Editor)
Three hunddred and sixty-eight pages of fungus -- the choice is yours.
|
|
|
Amphotericin B Colloidal Dispersion: An Advance in Antifungal Therapy (Chemotherapy Supplement)
by R. Herbrecht (Editor)
The papers in this text provide a study of amphotericin B colloidal dispersion and its use in antifungal therapy. Areas discussed include pre-clinical reviews and the use of amphotericin B against infections caused by aspergillus spp and candida spp.
|

|
MYCOCIDE NS Antifungal Care Kit with 2 Nail Grinders - 1 Oz
by WOODWARD LABORATORIES INC
MYCOCIDE NS Antifungal Care Kit cures most fungal skin infections, including athletes foot(tinea pedis) and ringworm (tinea corporis). Mycocide Antifungal Treatment Nail Solution. Kills More Germs than Antifungals. Developed by a Foot Doctor. Helps Nail Areas Look and Feel Better. No Need to Remove Polish or Acrylics. Includes 2 nail grinder files. Effectively relieves itching, burning, cracking and scaling accompanying such conditions Mycocide NS is a cost-effective, conservative first line solution. It features an aseptic dropper-tip applicator that delivers the medical strength fungus-killing formula directly to the site of infection without the increased risk of re-infecting the area with a contaminated brush applicator. Mycocide NS is patented and formulated to penetrate to the site...
|

|
Aroma Vera Aromatherapy Essential Oil Tea Tree - .5 fl oz (Pack of 2)
by Aroma Vera
Aromatherapy Essential Oil ~ Naturally Distilled 100% Pure Tea Tree For thousands of years mankind has used the power of Essential Oils to promote health, enhance beauty and influence mood. At Aroma Vera, we have spent the last 20 years continuing this tradition and refining our art, to ensure that you receive only the highest quality ingredients in every product we manufacture. Our Essential Oils are naturally distilled for maximum purity and potency.
|
|
|
Antifungal therapy too short in candidemia. (Low Compliance with IDSA Guidelines).: An article from: Internal Medicine News
by Bruce Jancin (Author)
This digital document is an article from Internal Medicine News, published by International Medical News Group on January 15, 2002. The length of the article is 453 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Antifungal therapy too short in candidemia. (Low Compliance with IDSA Guidelines). Author: Bruce Jancin Publication: Internal Medicine News (Magazine/Journal) Date: January 15, 2002 Publisher: International Medical News Group Volume: 35 Issue: 2 Page: 29(1)
Distributed by Thomson...
|
|